Quick Answer
Elicio Therapeutics, Inc. reported Stockholders Equity of $1.64 million for the year ending 2025.
- Elicio Therapeutics, Inc. showed an increase of +114.5% in Stockholders Equity from 2024 to 2025.
- This data is from Elicio Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$30.68 million | Q2 2020: -$49.10 million | Q3 2020: -$63.19 million | Q1 2021: $92.44 million | Q2 2021: $77.19 million | Q3 2021: $64.51 million | Q1 2022: -$81.44 million | Q2 2022: -$88.62 million | Q3 2022: -$95.70 million | Q1 2023: -$109.88 million | Q2 2023: $23.56 million | Q3 2023: $13.29 million | Q1 2024: $4.87 million | Q2 2024: -$1.65 million | Q3 2024: -$18.99 million | Q1 2025: $8.90 million | Q2 2025: $1.83 million | Q3 2025: $3.82 million.
- Over the full 7 years of available data (2019 to 2025), Elicio Therapeutics, Inc.'s Stockholders Equity has grown by 108.8%.
- Historical annual values: Fiscal year 2025: $1.64 million | Fiscal year 2024: -$11.31 million | Fiscal year 2023: $11.37 million | Fiscal year 2022: -$102.15 million | Fiscal year 2021: -$74.54 million | Fiscal year 2020: -$90.45 million | Fiscal year 2019: -$18.59 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: